EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSMAUG00000019162
Gene Symbol: GABRA5
4 Cross references
262 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSMAUG00000020508
Gene Symbol: GABRA6
4 Cross references
195 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta1

Ensembl ID : ENSMAUG00000018940
Gene Symbol: GABRB1
4 Cross references
102 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSMAUG00000012444
Gene Symbol: GABRB2
4 Cross references
275 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSMAUG00000008422
Gene Symbol: GABRB3
4 Cross references
263 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSMAUG00000010719
Gene Symbol: GABRD
4 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Epsilon

Ensembl ID : ENSMAUG00000001350
Gene Symbol: GABRE
3 Cross references
111 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Theta

Ensembl ID : ENSMAUG00000011778
Gene Symbol: GABRQ
4 Cross references
87 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSMAUG00000012954
Gene Symbol: GABBR1
4 Cross references
264 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSMAUG00000020850
Gene Symbol: LOC101841995
2 Cross references
191 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSMAUG00000021032
Gene Symbol: GIPR
3 Cross references
93 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSMAUG00000012802
Gene Symbol: GLP2R
3 Cross references
205 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).